The issue of comorbidity in the treatment of panic

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 4, 1998, Pages

  Dunner, David L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidity; Depression; Panic disorder

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DEPRESSION; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MICTURITION DISORDER; PANIC; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0031869670     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199804004-00004     Document Type: Review

References (40)

1. American Psychiatric Association (1987). DSM-III-R: Diagnostic and statistical manual of mental disorders. 3rd ed rev. Washington (DC): American Psychiatric Association.
2. American Psychiatric Association (1994). DSM-IV: Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association.
3. Andrade L, Eaton WW, Chilcoat H (1994). Lifetime comorbidity of panic attacks and major depression in a population-based study: symptom profiles. Br J Psychiatry 165: 363-369.
4. Benfield P, Heel R, Lewis SP (1986). Fluoxetine: a review of its pharmacodynamic and pharmacokinetic efficacy in depressive illness. Drugs 32:481-508.
5. Blazer DG, Kessler RC, McGonagle KA, Swartz MS (1994). The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 151:979-986.
6. Boyer WF (1992). Potential indications for the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 6 (suppl 5):5-12.
7. Boyer WF, Feighner JP (1991a). Side-effects of the serotonin reuptake inhibitors. In: Selective serotonin reuptake inhibitors. Feighner JP, Boyer WF (editors). Chichester: John Wiley. pp. 133-152.
8. Boyer WF, Feighner JP (1991b). Pharmacokinetics and drug interactions. In: Selective serotonin reuptake inhibitors. Feighner JP, Boyer WF (editors). Chichester: John Wiley. pp. 81-88.
9. Brown CS, Bryant SG (1988). Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharmacol 22:232-235.
10. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck MS (1996). Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 153:1293-1300.
11. Coryell W, Endicott J, Andreasen NC, Keller MB, Clayton PJ, Hirschfeld RMA, et al. (1988). Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 145:293-300.
12. Cox BJ, Direnfeld DM, Swinson RP, Norton GR (1994). Suicidal ideation and suicide attempts in panic disorder and social phobia. Am J Psychiatry 151:882-887.
13. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, Shrivastava RK (1991). A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 159:392-398.
14. Dunner DL (1997). Improving the quality of care of depressed patients with co-morbid psychiatric disorders: a review. Clin Performance Quality Healthcare 5:11-15.
15. Eaton WW, Kessler RC, Wittchen H-U, Magee WJ (1994). Panic and panic disorder in the United States. Am J Psychiatry 151:413-420.
16. Finley PR (1994). Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Phamacother 28:1359-1369.
17. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, et al. (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289-295.
18. Grunhaus L, Pande AC, Brown MB, Greden JF (1994). Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. Am J Psychiatry 151:541-546.
19. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH (1989). A review of the metabolism and pharmacokinetics for paroxetine in man. Acta Psychiatr Scand 80 (suppl):60-75.
20. Keller MB, Hanks DL (1995). Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 56 (suppl 6): 22-29.
21. Kessler RC (1997). Panic and depression: an American general population perspective [abstract]. In: Panic and depression: practical consequences for healthcare. SmithKline Beecham Satellite Symposium to the 6th World Congress of Biological Psychiatry, Sunday 22 June 1997, Nice, France. Welwyn Garden City (Herts): SmithKline Beecham.
22. Kessler RC, Frank RG (1997). The impact of psychiatric disorders on work loss days. Psychol Med 27:861-873.
23. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
24. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC (1997). Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54:313-321.
25. King MK, Schmaling KB, Cowley DS, Dunner DL (1995). Suicide attempt history in depressed patients with and without a history of panic attacks. Compr Psychiatry 36:25-30.
26. Lecrubier Y, Üstün TB (1998). Panic and depression: a worldwide primary care perspective. Int Clin Psychopharmacol 13 (suppl 4):S7-S11.
27. Lecrubier Y, Bakker A, Dunbar G, Judge R, and the Collaborative Paroxetine Panic Study Investigators (1997a). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95:145-152.
28. Lecrubier Y, Judge R, and the Collaborative Paroxetine Panic Study Investigators (1997b). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 95:153-160.
29. Lépine JP, Chignon JM, Teherani M (1993). Suicide attempts in patients with panic disorder. Arch Gen Psychiatry 50:144-149.
30. Montgomery SA, Bullock T, Fineberg B (1991). Serotonin selectivity for obsessive compulsive and panic disorders. J Psychiatry Neurosci 16 (suppl 1):30-35.
31. Montgomery SA, Dunner DL, Dunbar GC (1995). Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5:5-13.
32. Myers JK, Weissman MM, Tischler GL, Orvaschel H, Anthony JC, Boyd JH, et al. (1984). Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 41:959-967.
33. Reich J, Warsaw M, Peterson LG, White K, Keller M, Lavori P, Yonkers KA (1993). Comorbidity of panic and major depressive disorder. J Psychiatr Res 27 (suppl 1):23-33.
34. Rost K, Smith GR, Matthews DB, Guise B (1994). The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 3:333-337.
35. Sartorius N, Üstün TB, Lecrubier Y, Wittchen H-U (1996). Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 168 (suppl 30):38-43.
36. Stein MB, Tancer ME, Uhde TW (1990). Major depression in patients with panic disorder: factors associated with course and recuirence. J Affective Disord 19:287-296.
37. Vollrath M, Koch R, Angst J (1990). The Zurich Study. IX. Panic disorder and sporadic panic: symptoms, diagnosis, prevalence, and overlap with depression. Eur Arch Psychiatry Neurol Sci 239:221-230.
38. Warrington SJ (1992). Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol 7 (suppl 2):13-19.
39. Warshaw MG, Màssion AO, Peterson LG, Pratt LA, Keller MB (1995). Suicidal behaviour in patients with panic disorder: retrospective and prospective data. J Affective Disord 34:235-247.
40. Zohar J, Judge R, and the OCD Paroxetine Study Investigators (1996). Paroxetine versus clomipramine and placebo in the treatment of obsessive compulsive disorder. Br J Psychiatry 169:468-474.